PTC (NASDAQ:PTC – Get Free Report) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating ...

Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) have been given an average recommendation of “Moderate Buy” ...

PTC has been in a holding pattern, posting a small loss of 4.7% while floating around $160.81. The stock also fell short of ...

Sometimes, the headline numbers don't tell the whole story. That's definitely the case with industrial software company PTC ...

Looking back on design software stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including PTC (NASDAQ:PTC) and its peers. The demand for rich, interactive 2D, 3D, VR and AR ...

Proficio Capital Partners LLC purchased a new position in shares of PTC Inc. (NASDAQ:PTC – Free Report) in the fourth quarter, HoldingsChannel reports. The fund purchased 48,174 shares of the ...

It has been about a month since the last earnings report for PTC Inc. (PTC). Shares have lost about 6.4% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

PTC (NasdaqGS:PTC) experienced a 4.52% decline in its total shareholder returns over the past week, coinciding with the appointment of Trac Pham to its Board of Directors. Pham brings a strong record ...

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Friday after JPMorgan Chase & Co. raised their price target on the stock from $72.

Fintel reports that on March 11, 2025, B of A Securities upgraded their outlook for PTC Therapeutics (NasdaqGS:PTCT) from Underperform to Neutral. As of March 5, 2025, the average one-year price ...

Calumet (NASDAQ:CLMT) +10.2% in Monday's trading as UBS raised the maker of hydrocarbon products to Neutral from Sell with a ...